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Cost-effectiveness of zoledronic acid and strontium-89 as bone protecting 
treatments in addition to chemotherapy in patients with metastatic castrate-
refractory prostate cancer: results from the TRAPEZE trial (ISRCTN 12808747). 
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Abstract 
 
Objectives: To evaluate the cost-effectiveness of adding zoledronic acid (ZA) or strontium-
89 (Sr89) to standard docetaxel chemotherapy for patients with castrate-refractory prostate 
cancer (CRPC).  
Patients and methods: Data on resource use and quality of life for 707 patients collected 
prospectively in the TRAPEZE 2x2 factorial randomised trial (ISRCTN 12808747) were used to 
assess the cost-effectiveness of i) zoledronic acid versus no zoledronic acid (ZA vs. no ZA), 
and ii) strontium-89 versus no strontium-89 (Sr89 vs. no Sr89). Costs were estimated from 
the perspective of the NHS and included expenditures for trial treatments, concomitant 
medications and use of related hospital and primary care services. QALYs were calculated 
ĂĐĐŽƌĚŝŶŐ ƚŽ ƉĂƚŝĞŶƚƐ ? ƌĞƐƉŽŶƐĞƐ ƚŽ ƚŚĞ ŐĞŶĞƌŝĐ ƵƌŽYŽůY-5D-3L instrument. Results are 
expressed as incremental cost-effectiveness ratios (ICER) and cost-effectiveness 
acceptability curves.  
Results: The per-patient cost for ZA was £12,667, £251 higher than the equivalent cost in 
the no ZA group. Patients in the ZA group experienced on average 0.03 QALYs more than 
their counterparts in no ZA. The incremental cost-effectiveness ratio (ICER) for this 
comparison was £8,005. Sr89 was associated with a cost of £13,230, £1,365 higher than no 
Sr89, and a gain of 0.08 QALYs compared to no Sr89. The ICER for Sr89 was £16,884. The 
probabilities of ZA and Sr89 being cost-effective were  0.64 and 0.60, respectively. 
Conclusions: The addition of bone-targeting treatments to standard chemotherapy led to a 
small improvement in QALYs for a modest increase in cost (or cost-savings). ZA and Sr89 
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resulted in ICERs below conventional willingness-to-pay per QALY thresholds, suggesting 
that their addition to chemotherapy may represent a cost-effective use of resources. 
 
Keywords: castrate-refractory prostate cancer; cost-effectiveness analysis; quality of ilife; 
bone protecting treatments; zoledronic acid; strontium-89 
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Introduction 
Prostate cancer is one of the commonest types of cancer and a major health problem 
around the world. In 2012, more than 1.1 million men were diagnosed with prostate cancer 
making this the second most common male cancer worldwide, accounting for approximately 
15% of all newly diagnosed male cancers. [1] In the UK, prostate cancer is the commonest 
form of cancer, with approximately 42,000 men being diagnosed with the disease and 
almost 11,000 men dying from it annually. [2]  
Prostate cancer typically presents as local disease, but a significant proportion of patients 
progress despite initial treatment. Hormone therapy has been the main treatment for 
relapsed prostate cancer, [3] leading to responses typically lasting for 12 to 24 months. The 
period after failure of initial androgen deprivation therapy is now termed castrate-resistant 
prostate cancer (CRPC). [4] Following two landmark trials, chemotherapy with docetaxel and 
prednisolone (DP) is considered the bedrock of therapy for metastatic CRPC. [5, 6]  
In patients with metastatic disease, the commonest site of spread is bone. Two treatments 
approved for bone disease are zoledronic acid [7, 8] (ZA) and strontium-89 [9, 10] (Sr89). A 
pre-docetaxel era trial combined chemotherapy with Sr89 in a small randomised trial and 
suggested a survival advantage in patients allocated to Sr89. [11]  ZA is approved on the 
basis of reductions in skeletal-related events (SRE), a composite endpoint including 
symptomatic fractures, surgeries and radiotherapy to bone.  
There is considerable uncertainty as to whether the cost of adding bone-protecting 
treatments, such as ZA or Sr89, to standard chemotherapy would be warranted by improved 
quality of life (QoL) and reduced use of health care resources, possibly due to fewer 
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skeletal-related events. This question is particularly pertinent as zoledronic acid is now 
available as a generic product, at a considerably lower price than its branded counterpart.  
Given this, we sought to assess the cost effectiveness of adding bone-protecting treatments 
to docetaxel chemotherapy for patients with castrate-refractory prostate cancer (CRPC), 
using prospectively collected data from the TRAPEZE 2x2 factorial randomised controlled 
trial (ISRCTN 12808747). Two relevant comparisons were explored in the trial: i) zoledronic 
acid in addition to standard chemotherapy versus no zoledronic acid (ZA vs. no ZA), and ii) 
strontium-89 in addition to standard chemotherapy versus no strontium-89 (Sr89 vs. no 
Sr89).  
Patients and methods 
The TRAPEZE trial design is described in detail elsewhere [12, 13]. Briefly, this was a 
randomized open label phase III study using a 2x2 factorial design aiming to compare ZA vs. 
no ZA (stratified for Sr89) and Sr89 vs. no Sr89 (stratified for ZA). The trial recruited 757 
patients with progressive metastatic CRPC according to the following eligibility criteria: age 
A? ? ? ?K'ƐĐŽƌĞA? ? ?ĂŶĚĂĚĞƋƵĂƚĞŚĂĞŵĂƚŽůŽŐŝcal, renal and hepatic function. Participants 
were randomised to one of four arms: i) DP arm: docetaxel 75mg/m2 3-weekly and oral 
prednisolone 10 mg daily for up to 10 cycles; ii) DP+ZA arm: docetaxel and prednisolone plus 
zoledronic acid 4mg three weekly during chemotherapy then 4 weekly until disease 
progression; iii) DP+Sr89 arm: docetaxel and prednisolone for six cycles, strontium-89 150 
MBq then further docetaxel and prednisolone up to total of 10 cycles; iv) DP+ZA+Sr89 arm: 
docetaxel and prednisolone plus both strontium-89 and zoledronic acid as above. Ethical 
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approval was received from the Multicentre Research Ethics Committee and regulatory 
approval was granted by the UK Medicines and Healthcare Regulatory Agency.  
The primary outcome of the clinical analysis was clinical progression-free survival (CPFS), 
defined as the number of days from randomisation to the first occurrence of a symptomatic 
SRE, pain progression or death. The main outcome of the cost-effectiveness analysis is cost 
per quality-adjusted life year (QALY). Responses to EQ-5D needed for calculating QALYs and, 
thereby, cost-effectiveness in this trial were available for 707 (93%) of the 757 patients. This 
was a representative subgroup of the trial patients (Table S1). Patient characteristics are 
given in Table 1.  
Resource use and cost 
Data on health care resource use were collected prospectively through case report forms 
(CRF) and patient-completed questionnaires. Relevant resource use fell under three main 
categories: i) trial treatments; ii) concomitant treatments, and iii) use of other related 
hospital and primary care services. The cost of trial treatments was calculated according to 
patient-specific doses and number of treatment cycles provided, taking into account the 
cost of drug administration. The cost of care or medications provided concomitantly with 
trial treatment (radiotherapy, abiraterone, cabazitaxel, mitoxantrone, blood transfusions, 
additional docetaxel, strontium-89, zoledronic acid and surgical procedures) was obtained 
by weighting their respective use recorded in CRFs by unit costs available from national 
sources (Table 1) [14-17]. Outpatient appointments, inpatient stay and general practitioner 
visits were drawn from CRFs, while post-treatment hospital stay and visits were obtained 
from patient-completed questionnaires. Questionnaire data were missing for 126 patients  
and were imputed using multiple imputation by chained equations [18].  
7 
 
 
Quality of life and QALYs 
QALY scores were derived by translating responses to the EQ-5D-3L health status 
instrument [19] into preference-based (utility) scores using a standard value set [20]. EQ-5D 
was collected three weekly during treatment, then monthly for 3 months and 3 monthly 
until death. QALYs were calculated as the area under the curve connecting utility scores 
available at different time points. For patients who were known to have died, a utility of 
zero was assigned on the date of death [21]. For patients still alive at the time of analysis, 
their last known EQ-5D-3L score was carried forward to the date last seen. 
Cost-effectiveness analysis 
Analyses were conducted from the perspective of the National Health System in the UK. In 
line with recommendations, costs and benefits accruing beyond 12 months were discounted 
at a rate of 3.5% per year [22]. A total cost and a total number of QALYs were calculated for 
each patient, with 95% confidence intervals around mean values obtained through 1000 
bias corrected and accelerated (BCa) bootstrap replications [23, 24]. Given the short 
expected survival time of metastatic CRPC patients and the long-term follow-up of patients 
in the trial, lifetime costs and effects were largely observed and so extrapolation beyond the 
trial was unnecessary. In the comparison between ZA and no ZA, the main analysis was 
based on the fact that, as of 2013, zoledronic acid has been available as a generic product, 
at a price significantly lower than its branded counterparts. Additional analyses were 
conducted on the basis of the proprietary product. 
Differences in mean total costs and QALYs between the compared options were presented 
as incremental cost-effectiveness ratios (ICERs), a measure reflecting the additional cost 
associated with a gain of an additional QALY [25]. To account for uncertainty in the results, 
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nonparametric bootstrapping was used to replicate the joint distribution of the differences 
in cost and QALYs [26]. This generated 5000 paired estimates of incremental costs and 
QALYs, which were subsequently used to derive cost-effectiveness acceptability curves 
(CEACs) [27]. CEACs show the probability of each option being cost-effective across a range 
of possible values of willingness to pay (ceiling ratio) for an additional QALY [28]. The impact 
of alternative assumptions and uncertain values on the results was explored in additional 
sensitivity analyses. 
Results 
Comparison of ZA vs no ZA 
Cost by resource use category, total costs and total QALYs for the comparison between ZA 
and no ZA are given in (Table 2). The most substantial difference in costs was due to the use 
of zoledronic acid itself provided as protocol and follow-up treatment in the ZA group. With 
the exception of zoledronic acid, patients in the ZA group presented lower use of additional 
care and medications. Notably, there were differences in the use of radiotherapy and 
surgery, reflective of the fact that patients in the ZA group experienced fewer SREs. The 
difference in total costs between ZA and no ZA was £251 (BCa 95% CIs: -£1099 to £1602); 
this difference was contingent on the acquisition cost of zoledronic acid. In relation to 
health benefits, patients in the ZA group had an average of 0.91 QALYs, reflecting a gain of 
0.03 QALYs (BCa 95% CI: -0.07 to 0.13) over their counterparts in the no ZA group.  
Combining differences in costs and QALYs resulted in an ICER of £8005 per QALY. At the 
commonly-cited lower willingness-to-pay ratio of £20,000 per QALY in the UK [22, 29-33], 
the probability of ZA being cost-effective is 0.64 (Figure 1). For prices of zoledronic acid 
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between £0 and £31, the total per-patient cost of ZA is lower than that of no ZA and, given 
the fact that ZA is associated with a slight increase in QALYs, this treatment option 
dominates its comparator. For prices between £31 and £98, ZA results in ICERs up to 
£20,000 per QALY, and it is thus cost-effective at this willingness-to-pay value.  
Most of the alternative assumptions explored in additional sensitivity analyses (e.g. different 
prices of concomitant medications, no discounting etc.) had a small, proportional effect on 
the additional cost and benefits of each treatment option, and, thus, they had a minimal 
impact on the resulting ICER (Table S2). The only exception was the adjustment of QALYs for 
baseline imbalances in EQ-5D scores, which resulted in a very small, non-significant 
difference in QALYs in favour of no ZA (0.0006 QALYs, CIs: -0.096 to 0.094). For zoledronic 
acid prices up to £28, ZA is less costly and less effective, but overall more cost-effective than 
no ZA (at £20,000 per QALY foregone), and it is more costly and less effective (i.e. 
dominated) above this price (Figure S1).  
Comparison of Sr89 vs no Sr89 
The most prominent difference in mean costs between the Sr89 and no Sr89 groups was 
due to the use of strontium-89 itself. Apart from the higher cost for strontium-89, the Sr89 
group was associated with greater cost for docetaxel and zoledronic acid given as protocol 
treatments, higher cost for cabazitaxel and docetaxel provided as concomitant medications, 
and increased cost due to surgeries. On the other hand, the Sr89 group was associated with 
fewer radiotherapies, lower use of abiraterone, zoledronic acid and strontium-89 as 
concomitant medications, and fewer inpatient days, outpatient appointments and GP visits 
(Table 3). The analysis showed mean total costs per person of £13,230 and £11,865 for Sr89 
and no Sr89 respectively, resulting in a mean difference of £1365 (BCa 95% CIs: -£12 to 
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£2,742). For the comparison between Sr89 vs no Sr89, patients who received Sr89 showed a 
gain of 0.08 QALYs (BCa 95% CIs: -0.019 to 0.181) over those in the no Sr89 group. 
Overall, Sr89 was associated with a higher total per-patient cost and a greater mean number 
of QALYs compared to no Sr89. Given these differences, the point estimate ICER for Sr89 
was calculated at £16,884 per additional QALY. At a willingness-to-pay value of £20,000 for 
an additional QALY, the probability that Sr89 is cost-effective is 0.6 (Figure 2). The ICER for 
Sr89 remains bellow £20,000 per QALY for prices of strontium-89 up to £2120. 
Most of the alternative scenarios explored in sensitivity analyses had a limited impact on the 
magnitude of the results and did not change the baseline conclusion for this comparison 
(Table S2). An exception was the analysis using different prices for strontium-89: a lower 
price of strontium-89 gives an ICER of £13,182 per QALY, whereas a higher price resulted in 
an ICER of £20,585 per QALY. 
Discussion  
This study uses patient level data collected in the TRAPEZE trial to determine whether the 
addition of ZA or Sr89 bone-protecting therapies to standard chemotherapy represents a 
cost-effective use of healthcare resources. 
The comparison between ZA and no ZA showed ZA to be associated with a small additional 
cost for a slight improvement in QALYs. This additional cost was relatively modest, owing to 
the low additional cost for zoledronic acid and the fact that this cost was largely 
counterbalanced by reduced use of other healthcare resources (e.g. fewer radiotherapies 
and surgeries). Prevention of serious events such as fracture, surgery and cord compression 
is seen as a desirable outcome for the NHS [34]; therefore, a predictable, outpatient therapy 
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with modest net acquisition costs may be attractive to providers if it prevents emergency, 
unpredictable visits. In the likely case that the NHS pay less than £31 for a dose of zoledronic 
acid, ZA is the dominant option, being less costly and more effective than no ZA.  
The magnitude of the additional cost in the ZA group is to a great extent dependent on the 
acquisition cost of zoledronic acid. Since 2013, zoledronic acid is available as a generic 
product, at a price markedly lower than the equivalent proprietary products (Zometa® and 
Aclasta®). Given the average price paid by NHS hospitals for zoledronic acid in the UK, the 
additional cost of ZA was low, at £251, resulting in an attractive ICER of about £8,000 per 
QALY. In the likely case that the NHS pay less than £31 for a dose of zoledronic acid, ZA is 
the dominant option (i.e. less costly and more effective, in terms of QALYs, than no ZA).  
The Sr89 group was associated with an increase in cost and an improvement in QALYs, 
which translated into an ICER of £16,900 per QALY. However, these results will need to be 
seen in light of the fact that a number of new treatments licenced in the last few years have 
now emerged, including abiraterone, enzalutamide, cabazitaxel and, of particular relevance 
to this study, radium-223.  
For both the comparison between ZA vs no ZA and Sr89 vs no Sr89, the calculated 
confidence intervals of the differences in QALYs overlapped zero, suggesting that the 
observed improvements in QALYs are not statistically significant. However, given the fact 
that the TRAPEZE trial was not powered to detect statistically significant differences in 
QALYs, the observed results should not be interpreted as conclusive evidence of presence or 
absence of a significant difference. In line with recommendations, the interpretation of the 
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results is based on the outcome of the incremental cost-effectiveness ratios and the 
uncertainty surrounding them [25, 35].  
To our knowledge, this is the first economic evaluation based on prospectively collected 
data aiming to assess the cost-effectiveness of providing CRPC patients with ZA and Sr89 in 
addition to standard chemotherapy. A major strength of this study lies in the fact that data 
were obtained from a large pragmatic randomised controlled trial. In line with guidance in 
conducting economic evaluations, costs were estimated by weighting prospectively-
collected patient-level resource use by unit costs drawn from national sources, health 
benefits were measured using a widely used preference-based measure, and analyses of the 
collected data were performed using recommended statistical methods [24, 36-38]. While 
the analysis was carried out from the perspective of the NHS in the UK, the fact that the 
care pathway for CRPC is similar across developed countries makes the findings pertinent to 
other health care systems.  
Despite this, the study presents certain methodological challenges. First, ZA appeared to 
have a minimal effect on QoL, which did not tally with the marked change in the number 
and severity of SREs. Given that events such as pain leading to radiotherapy, fracture and 
spinal cord compression must certainly impair QoL, it is possible that temporary drops in 
QoL due to unpredictable SREs may have not been captured. This may be explained by the 
fact that EQ-5D forms are typically completed at predetermined points after randomisation, 
which are likely to fall either before SREs or after problems are resolved. Failure to capture 
temporary declines in QoL due to SREs indirectly penalises groups associated with fewer 
SREs ? in this case, the ZA group. Secondly, similarly to all trials, prospectively collected data 
are bound to be incomplete. In particular, final terminal phase SREs, resource use and 
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benefits are difficult to capture, as patients are generally less likely to attend trial clinics in 
that period [39, 40]. Last, while the trial protocol made provisions for six cycles of docetaxel 
ĐŚĞŵŽƚŚĞƌĂƉǇƉůƵƐĂŶĂĚĚŝƚŝŽŶĂůĨŽƵƌĐǇĐůĞƐ ‘ŽĨĨƐƚƵĚǇ ? ?E/ŝŶƚŚĞh<ƌĞĐŽŵŵĞŶĚĞĚƚŚĂƚ
up to 10 cycles of docetaxel chemotherapy should be administered in one treatment block. 
Given the intended pragmatic nature of this trial, adopting the NICE recommendation 
ĞŶƐƵƌĞĚ ƚŚĂƚ ƚƌĞĂƚŵĞŶƚĂƌŵƐ ƌĞĨůĞĐƚĞĚƚŚĞ ƚƌƵĞ  ‘ƐƚĂŶĚĂƌĚŽĨ ĐĂƌĞ ? ?KǁŝŶŐ ƚŽ ƚŚĞ ĨĂĐƚ ƚŚĂƚ
docetaxel chemotherapy was provided across all treatment groups, this change is not 
expected to impact on a particular treatment group over another. 
Further research in the area would be valuable. Despite the patient-level evidence obtained 
from the trial, more detailed estimates of QoL associated with SREs and use of healthcare 
resources would be useful. The latter is typically accessible via the Hospital Episode 
Statistics (HES) database, which contains details of all admissions, outpatient appointments 
and emergency attendances at NHS hospitals [41]. Further analyses using HES will give the 
opportunity to corroborate the study findings. In addition, it would be interesting to obtain 
insights into the clinical effectiveness and cost-effectiveness of both ZA and Sr89 as 
compared to neither treatment. While the TRAPEZE trial was not designed to investigate 
such comparisons, this could be pursued in a future study specifically designed to assess the 
particular treatment options. 
In conclusion, findings suggest that the addition of bone targeting treatments to standard 
chemotherapy lead to a small positive change in QALYs for a small additional cost (or cost-
savings), resulting in an ICER below the threshold of £20,000 per QALY. These cost-
effectiveness results, coupled with the treatmentƐ ? positive impact on SRE prevention, 
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suggest that supplementation of chemotherapy with bone-protecting treatments is likely to 
represent a cost-effective use of the available health care resources.  
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Legends to illustrations 
Figure 1. Cost Effectiveness Acceptability Curve showing the probability of ZA being cost-
effective at different values of willingness to pay per additional QALY 
Figure 2. Cost Effectiveness Acceptability Curve showing the probability of Sr89 being cost-
effective at different values of willingness to pay per additional QALY. 
Figure S1. Graph showing Incremental Cost Effectiveness Ratio for ZA vs no ZA at different 
prices of zoledronic acid, after adjusting for baseline imbalances in EQ-5D-3L  
 
Tables and legends 
Table 1. Unit cost prices and sources 
Table 2. Mean per-patient cost and QALYs for ZA vs no ZA 
Table 3. Mean per-patient cost and QALYS for Sr89 vs no Sr89 
Table S1. Summary characteristics of participants included in the economic evaluation 
(n=707) and all study participants (n=757) 
Table S2. Results of sensitivity analyses for ZA vs no ZA and Sr89 vs no Sr89. 
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Tables 
Table 1. Unit cost prices and sources 
Item Cost Source 
Docetaxel £155 (for 1ml vial (20mg)) British National Formulary
14 
Prednisolone £0.64 per day British National Formulary
14
 
Zoledronic acid £58 (for 4mg) NHS Commercial Medicines Unit
17
 
Strontium-89 £1710 (per fraction of 150mbq) Nuclear Medicine Department, 
University Hospital Birmingham. 
Abiraterone £98 per day British National Formulary
14
 
Cabazitaxel £3696 per cycle British National Formulary
14
 
Mitoxantrone £100 per cycle British National Formulary
14
 
Radiotherapy £813 cost of radiotherapy preparation 
plus 
£118  cost of radiotherapy fraction 
NHS Reference Costs
16
 
Blood £123 per unit plus intravenous cannula 
(£1) and blood giving set (£4) 
NHS Blood and Transplant 
Administration of DP, ZA 
(standalone), mitoxandrone 
£245 NHS Reference Cost
16
 
Administration cabazitaxel £144 NHS Reference Cost
16
 
Administration of Sr89 £443 Nuclear Medicine Department, 
University Hospital Birmingham 
Blood transfusion £172 NHS Reference Cost
16
 
Decompression for spinal 
cord compression 
£9,573 NHS Reference Cost
16
 
Laminectomy £6,893 NHS Reference Cost
16
 
Intramedullary nailing £4,995 NHS Reference Cost
16
 
Hip replacement £8,038 NHS Reference Cost
16
 
Fracture £3,888 NHS Reference Cost
16
 
Spinal cord compression £7,816 NHS Reference Cost
16
 
Inpatient stay £680 NHS Reference Cost
16
 
Outpatient appointment £135 Personal Social Services Research 
Unit
15
 
GP consultation £63 Personal Social Services Research 
Unit
15
 
 
  
21 
 
 
Table 2. Mean per-patient cost and QALYs for ZA vs no ZA 
  ZA (n=350) No ZA (n=357) 
 
Difference (ZA vs. no ZA) 
 
  
Mean SD Mean SD 
Mean 
difference 
Lower 
95% CI* 
Upper 
95%  
CI* 
Trial treatment 
Docetaxel + prednisolone £2,502 £760 £2,441 £749 £60 -£49 £169 
Zoledronic acid £346 £151 £0 £0 £346 £330 £361 
Strontium-89 £769 £1,033 £724 £1,018 £45 -£107 £197 
Zoledronic acid as follow-up 
treatment 
£837 £1,358 £3 £48 £834 £692 £977 
Concomitant medications and treatments 
Radiotherapy £764 £1,093 £1,021 £1,264 -£257 -£429 -£85 
Abiraterone £1,811 £4,198 £2,150 £4,478 -£339 -£993 £316 
Zoledronic acid as concomitant 
medication 
£235 £801 £101 £492 £134 £36 £230 
Strontium-89 as concomitant 
medication 
£98 £476 £132 £539 -£34 -£109 £41 
Blood units £23 £150 £19 £125 £4 -£16 £24 
Cabazitaxel £301 £1,710 £293 £2,230 £8 -£288 £304 
Docetaxel as concomitant 
medication 
£372 £1,543 £433 £2,049 -£61 -£338 £216 
Mitoxantrone  £51 £245 £26 £179 £25 -£6 £56 
Surgery £116 £988 £377 £1,974 -£261 -£495 -£27 
Outpatient appointments and inpatient stay 
Hospital outpatient appointment £672 £1,015 £591 £804 £81 -£51 £213 
Hospital inpatient stay £3,494 £6,216 £3,786 £6,562 -£292 -£1,217 £632 
GP appointments £278 £319 £319 £384 -£42 -£95 £12 
TOTAL COST £12,667 £8,795 £12,417 £9,433 £251 -£1,099 £1,602 
TOTAL QALYs 0.908 0.683 0.876 0.693 0.031 -0.07 0.133 
* Obtained using the bias corrected and accelerated bootstrap method (1000 replications)  
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Table 3. Mean per-patient cost and QALYS for Sr89 vs no Sr89 
  Sr89 (n=350) 
  
No Sr89 (n=357) 
  
Difference (Sr89 vs no Sr89) 
  
Mean SD Mean SD 
Mean 
difference 
Lower 
95% CI* 
Upper 
95%  
CI* 
Trial treatment 
Docetaxel + prednisolone £2,497 £738 £2,445 £771 £52 -£61 £165 
Zoledronic acid £174 £203 £168 £203 £6 -£23 £35 
Strontium 89 £1,507 £988 £0 £0 £1,507 £1,407 £1,608 
Zoledronic acid as follow-up 
treatment 
£391 £965 £440 £1,114 -£49 -£197 £100 
Concomitant medications and treatments 
Radiotherapy £803 £1,033 £983 £1,318 -£180 -£349 -£11 
Abiraterone £1,905 £4,279 £2,058 £4,408 -£153 -£814 £508 
Zoledronic acid as concomitant 
medication 
£148 £625 £187 £704 -£39 -£139 £61 
Strontium-89 as concomitant 
medication 
£110 £527 £120 £492 -£9 -£85 £66 
Blood units £21 £150 £21 £124 £0 -£20 £21 
Cabazitaxel £375 £2,192 £221 £1,765 £154 -£134 £443 
Docetaxel as concomitant 
medication 
£415 £2,057 £390 £1,545 £25 -£233 £283 
Mitoxantrone  £39 £218 £39 £211 £0 -£32 £31 
Surgery £325 £1,954 £172 £1,064 £153 -£84 £390 
Outpatient appointments and inpatient stay 
Hospital outpatient appointment £609 £889 £653 £940 -£44 -£178 £89 
Hospital inpatient stay £3,630 £6,294 £3,653 £6,491 -£23 -£950 £903 
GP appointments £281 £350 £316 £357 -£35 -£86 £16 
TOTAL COST £13,230 £9,105 £11,865 £9,091 £1,365 -£12 £2,742 
TOTAL QALYs 0.933 0.725 0.852 0.648 0.081 -0.019 0.181 
* Obtained using the bias corrected and accelerated bootstrap method (1000 replications) 
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Figure 1. Cost Effectiveness Acceptability Curve showing the probability of ZA being cost-effective at different values of 
willingness to pay per additional QALY 
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Figure 2. Cost Effectiveness Acceptability Curve showing the probability of Sr89 being cost-effective at different values of 
willingness to pay per additional QALY. 
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Supplementary material 
Table S1. Summary characteristics of participants included in the economic evaluation (n=707) and all study participants 
(n=757) 
 
Economic analysis subset 
(n=707) 
 
All TRAPEZE trial participants 
(n=757) 
 
Age  
median (IQR) 
68 (64, 73) 68 (63, 73) 
PSA  
median (IQR) 
143.75 (49.8, 347.6) 145.55 (51.2, 353.58) 
ECOG n(%)                                          0 291 (41.16) 305 (40.29) 
1 361 (51.06) 389 (51.39) 
2 55 (7.78) 63 (8.32) 
Prior Radiotherapy  
n (%) 
331 (44.30%) 337 (44.87%) 
Daily Present Pain Index (scale 0.5)        
median (IQR) 
 
1.43 (0.86, 2.00) 1.43 (0.86, 2.00) 
Daily Analgesic Score  
median (IQR) 
10.01 (0.86, 27.63) 10.21 (0.88, 27.89) 
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Table S2. Results of sensitivity analyses for ZA vs no ZA and Sr89 vs no Sr89. 
  
  
ZA no ZA 
ICER ZA vs 
no ZA 
Sr89 no Sr89 
ICER Sr89 vs 
no Sr89 Mean Cost Mean 
QALYs 
Mean Cost Mean 
QALYs 
Mean 
Cost 
Mean 
QALYs 
Mean 
Cost 
Mean 
QALYs 
Base case results £12,668 0.908 £12,417 0.876 £8,005 £13,230 0.933 £11,865 0.852 £16,884 
No discounting £12,788 0.915 £12,552 0.884 £7,684 £13,362 0.941 £11,988 0.859 £16,806 
Unit cost of mitoxantrone from NHS 
electronic Market Information Tool 
(£60.36 for 25mg) 
£12,662 0.908 £12,414 0.876 £7,914 £13,226 0.933 £11,861 0.852 £16,884 
Unit cost of docetaxel taken from NHS 
electronic Market Information Tool 
(£34.29 for 140mg) 
£11,515 0.908 £11,227 0.876 £9,196 £12,041 0.933 £10,712 0.852 £16,448 
Unit cost of strontium-89 (75% of base 
case estimate) 
£12,515 0.908 £12,273 0.876 £7,718 £12,931 0.933 £11,865 0.852 £13,182 
Unit cost of strontium-89 (125% of 
base case estimate) 
£12,821 0.908 £12,561 0.876 £8,291 £13,530 0.933 £11,865 0.852 £20,585 
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Figure S1. Graph showing Incremental Cost Effectiveness Ratio for ZA vs no ZA at different prices of zoledronic acid, after 
adjusting for baseline imbalances in EQ-5D-3L  
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